数据
资源
版本对比
免费注册
预约演示
免费注册
Valbiotis
Accelerates Its Marketing Strategy - October 07, 2022
2022-10-07
·
BioSpace
合作
Internationally, the signing of licensing or distribution partnerships with major players in nutrition and healthcare. In France,
Valbiotis
has chosen to internalize its commercial operations for direct distribution, in order to generate rapid turnover and to ensure an independent and value-creating source of income. Continued structuring and R&D efforts on natural and scientifically validated active substances in the prevention of
cardio-metabolic diseases
. LA ROCHELLE, France--(BUSINESS WIRE)-- Regulatory News:
Valbiotis
(FR0013254851 – ALVAL, PEA / SME eligible), a
Research and Development company
committed to scientific innovation for preventing and combating
metabolic and cardiovascular diseases
, is accelerating its marketing strategy. Sébastien PELTIER, Chairman of the
Valbiotis
Board of Directors, states: "Today, we are embarking on a complementary development cycle to commercialize our innovative active substances, with the aim of providing breakthrough solutions for reducing the risk factors of
cardio-metabolic diseases
. Our new strategy aims to accelerate the growth of
Valbiotis
and to boost its capacity for innovation using two main levers: firstly, the signing of international partnerships (global or regional) with major players in the nutrition and healthcare sectors, supported by the specialist firm AEC Partners1, and secondly, the company's own marketing of its products on the French market. This dual strategy, creating value, will enable
Valbiotis
to rapidly target the global food supplement market, estimated at 250 billion euros in 2025, with annual growth of 9.6%, including 3.2 billion euros for France, with annual growth of 7.3%2. The exponential demand for natural, non-drug preventive products, market studies3 conducted with healthcare professionals and patients/consumers, combined with our recent positive Phase II clinical results for TOTUM•070, have led us to adapt our marketing strategy." Committed to preventing and fighting
metabolic and cardiovascular diseases
through the development of unique combinations of plant-based molecules since 2014,
Valbiotis
now has a portfolio of four active substances in late-stage development with TOTUM•63 in
prediabetes
, TOTUM•070 in
LDL hypercholesterolemia
("bad cholesterol"), TOTUM•854 in the reduction of blood pressure, and TOTUM•448 in the management of
metabolic liver disease
(NAFL and
NASH
). This solid pipeline of four products with proven efficacy based on preclinical and clinical data is the result of eight years of sustained R&D activities. Today,
Valbiotis
is entering a new phase of its development focused on revenue generation and structuring the Company to give this product portfolio every chance of success on a global scale. Organization around three strategic priorities for
Valbiotis
First, the search for international licensing or distribution agreements for TOTUM•070, TOTUM•448 and TOTUM•854 with major nutrition and health players, in addition to the global strategic partnership already signed for TOTUM•63 in February 2020 with Nestlé Health Science. This key activity is supported by
AEC Partners
, the firm that has already worked on the partnership with
Nestlé Health Science
on behalf of
Valbiotis
, and by the creation of an internal business development and co-leadership team. Second, the direct marketing in France of TOTUM•070, TOTUM•448 and TOTUM•854 will ensure that
Valbiotis
can rapidly and independently develop its turnover and maximize its profitability in the medium term. Third,
Valbiotis
will continue its structuring to secure the supply chain for future commercializations, and will maintain its research efforts to prepare tomorrow's pipeline and complete clinical processes to obtain proprietary health claims for the majority of them. Marketing of the TOTUM active substances prior to obtaining these proprietary health claims will allow to address significant needs, currently not appropriately met, in the prevention of
cardio-metabolic diseases
as soon as possible. In the United States and Europe alone (TOP 54), 174 million adults are affected by moderate
hypercholesterolemia
, 124 million by moderate elevated blood pressure and 130 million by
metabolic liver disease5
. In these target populations, the demand for both effective preventive products and plant-based substances is driven by powerful underlying trends. Internationally, the signing of licensing or distribution agreements With its portfolio of four TOTUM active substances that have demonstrated their efficacy in these widely occurring pathologies,
Valbiotis
is confident in its ability to enter into licensing or distribution agreements with major nutrition and healthcare players in the near future, with a view to marketing them internationally. The consulting firm
AEC Partners
is supporting
Valbiotis
in this search for new large-scale partnerships, following the one signed in February 2020 with Nestlé Health Science worldwide for TOTUM•63, now in the final phase of clinical studies (Phase II/III). The new licensing or distribution partnerships will be global (except for France) or regional.
Valbiotis
' ambition is to finalize the signature of international licensing or distribution agreements for TOTUM•070 by the second half of 2023. In France, the deployment of a direct marketing model In France, apart from TOTUM•63 which benefits from a 100% worldwide partnership with
Nestlé Health Science
, the other three active substances will be marketed directly by
Valbiotis
. The marketing strategy will be based on in-house medical promotion officers (APMs) who will focus on key prescribers such as general practitioners, certain specialists and pharmacists. The latter will recommend the TOTUM active substances based on the cardiometabolic pro their patients. At the same time, consumers/patients will be targeted directly through an adapted digital marketing strategy. The distribution channels envisaged will be pharmacies, drugstores and online sales. TOTUM•070, whose Phase II clinical study was highly successful, will be the first product marketed by Valbiotis in France. It is scheduled to be launched in the first half of 2024, followed by TOTUM•448 and TOTUM•854 in 2024-2025. Continued structuring and research efforts The third strategic priority is to continue structuring the company with the aim of optimizing the value chain for the supply of TOTUM•63, as provided for in the contract with
Nestlé Health Science
, but also to develop capabilities for the other products in the portfolio. At the same time, innovation efforts will continue.
Valbiotis
' proprietary R&D platform, specifically designed for plant research, will remain at the heart of the company's DNA, in order to feed the pipeline of the coming years, including the exploration of micro-algae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER (press release of September 24, 2021). The execution of the strategy will be financed by
Valbiotis
' cash flow and the expected revenues from the partnership with
Nestlé Health Science
(which has already generated 8 million euros in cash since its signature). It is also conditional on obtaining additional financing, the terms of which are currently being studied. About
Valbiotis
Valbiotis
is a
Research & Development company
committed to scientific innovation for preventing and combating
metabolic and cardiovascular diseases
in response to unmet medical needs.
Valbiotis
has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major
metabolic diseases
, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources. Its products are intended to be licensed to players in the health sector. Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and
Riom
(63) – and a subsidiary in Quebec City (Canada).
Valbiotis
is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label.
Valbiotis
has also been awarded "
Young Innovative Company
" status and has received major financial support from the European Union for its research programs via the
European Regional Development
Fund (ERDF).
Valbiotis
is a PEA-SME eligible company. For more information about
Valbiotis
, please visit: Name:
Valbiotis
ISIN code: FR0013254851 Ticker symbol: ALVAL EnterNext© PEA-PME 150 This press release contains forward-looking statements about
Valbiotis
’ objectives.
Valbiotis
considers that these projections are based on rational hypotheses and the information available to
Valbiotis
at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the
Valbiotis
Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022. This document is available on the Company’s website ( ). This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to
Valbiotis
’ shares or financial securities in any country. _____________________________ 1 AEC Partners: a life sciences firm specializing in market access, licensing and strategy consulting. 2 Panorama of the food supplements market 2020-2021, Nutrikeo. 3 Medical-marketing studies conducted in 2022 by IFOP and A+A at the request of
Valbiotis
, in France, Germany and the United States. 4 France, Germany, Italy, Spain, United Kingdom 5 Elevated LDL, pre-HTA and NAFL preliminary market estimation,
AEC Partners
, 2020 View source version on businesswire.com: Contacts Corporate communication /
Valbiotis
Carole ROCHER Communication and Public Affairs Director Marc DELAUNAY Communication Manager +33 5 46 28 62 58 media@valbiotis.com Media relations / PrPa Damien MAILLARD Operational Director +33 6 80 28 47 70 damien.maillard@prpa.fr Financial communication / Actifin Stéphane RUIZ Associate Director +33 1 56 88 11 14 sruiz@actifin.fr Loris DAOUGABEL Media relations +33 1 56 88 11 16 ldaougabel@actifin.fr Source:
Valbiotis
View this news release online at:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Nestle Health Science SA
European Regional Development Fund
Valbiotis SA
[+5]
适应症
代谢性疾病
心血管疾病
葡萄糖耐受不良
[+4]
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务